LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Accueil・Liste d'Actions・uniQure NV

uniQure NV

Fermé

26.7 -4.91

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.23

Max

28.08

Chiffres clés
By Trading Economics
Revenu	-16M -54M
Ventes	-2M 3.6M
BPA	-0.73
Marge bénéficiaire	-1,502.948
Employés	221
EBITDA	13M -36M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+49.22% upside

Dividendes
By Dow Jones
Prochains Résultats	28 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	476M 1.8B
Ouverture précédente	31.61
Clôture précédente	26.7

uniQure NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 mars 2026, 13:13 UTC

Principaux Mouvements du Marché

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 janv. 2026, 15:14 UTC

Principaux Mouvements du Marché

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov. 2025, 13:34 UTC

Principaux Mouvements du Marché

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 sept. 2025, 18:51 UTC

Résultats

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Comparaison

Variation de prix

uniQure NV prévision

Objectif de Prix

By TipRanks

49.22% hausse

Prévisions sur 12 Mois

Moyen 42.11 USD 49.22%

Haut 95 USD

Bas 14 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.